- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02733588
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2a, single-center, open-label, proof-of-concept study designed to test the ability of the control algorithm to detect and direct timing of G-Pump™ glucagon infused from an OmniPod® pump to prevent hypoglycemia in patients with post-bariatric hypoglycemia syndrome. While the algorithm will provide an alert as to when glucagon should be dosed to prevent hypoglycemia, there will be no automation in this clinical trial and it will ultimately be up to the physician to initiate dosing via the OmniPod® controller.
Participant on continuous glucose monitoring will arrive at the clinic and IV line will be inserted for venous access. Subject will then be asked to drink a liquid mixed meal containing 60 g of carbohydrates, e.g. Boost® Nutritional Drink, over 10 minutes. Blood samples will be collected for glucose and hormone measurement.
The open-loop system will be set to recognize low sensor glucose values, triggering an alert to the physician, who will deliver a bolus of 150 or 300 µg of glucagon via the pump, with the goal of preventing further decline in glucose values. Depending on response, a second bolus dose of 150 or 300 µg of glucagon may be administered. Plasma glucose will be measured after glucagon administration to ensure successful treatment and glucose stability, and glucagon levels will be analyzed concurrently to determine magnitude of increase above baseline. Sensors will be downloaded for subsequent analysis of appropriateness of alert timing and trigger for glucagon bolus delivery.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose.
- willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.
Exclusion Criteria:
- documented hypoglycemia occurring in the fasting state (> 12 hours fast);
- chronic kidney disease stage 4 or 5;
- hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin > 2.0;
- congestive heart failure, New York Heart Association class II, III or IV;
- history of myocardial infarction, unstable angina or revascularization within the past 6 months;
- history of a cerebrovascular accident;
- seizure disorder (other than with suspect or documented hypoglycemia);
- active treatment with any diabetes medications except for acarbose;
- active malignancy, except basal cell or squamous cell skin cancers;
- personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);
- known insulinoma;
- major surgical operation within 30 days prior to screening;
- hematocrit ≤ 33%;
- bleeding disorder, treatment with warfarin, or platelet count <50,000;
- blood donation (1 pint of whole blood) within the past 2 months;
- active alcohol abuse or substance abuse;
- current administration of oral or parenteral corticosteroids;
- pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.
- use of an investigational drug within 30 days prior to screening.
- there will be no involvement of special vulnerable populations such as pregnant women, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: G-Pump™ (glucagon infusion)
0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
|
0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection/Notification of Hypoglycemia
Time Frame: 0 - 120 minutes following dosing
|
Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose < 75 mg/dl) and notifies the investigator to initiate treatment.
Reported as the number of successful identifications.
|
0 - 120 minutes following dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Severe Hypoglycemia
Time Frame: 0 - 120 minutes following dosing
|
Frequency of severe hypoglycemia defined as glucose levels below 60 mg/dl.
Reported as the number of subjects with severe hypoglycemia.
|
0 - 120 minutes following dosing
|
Number of Subjects With Rebound Hyperglycemia
Time Frame: 0 - 120 minutes following dosing
|
Frequency of rebound hyperglycemia defined as glucose levels above 180 mg/dl.
Reported as the number of subjects with rebound hyperglycemia.
|
0 - 120 minutes following dosing
|
Glucose Time in Range
Time Frame: 0 - 120 minutes following dosing
|
Time glucose remains in goal range, 60-180 mg/dl, reported in minutes
|
0 - 120 minutes following dosing
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XSGO-PB01
- 1R44DK107114-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
University of UlmRecruitingHypoglycemia, ReactiveGermany
-
University of ArizonaNot yet recruiting
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Zealand University HospitalUnknownHypoglycemia, ReactiveDenmark
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
-
Vogenx, Inc.CompletedPostbariatric HypoglycemiaUnited States
-
Stanford UniversityCompletedNeonatal HypoglycemiaUnited States
-
Diva De LeonLester and Liesel Baker FoundationCompletedPostprandial HypoglycemiaUnited States
Clinical Trials on G-Pump™ (glucagon infusion)
-
Xeris PharmaceuticalsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...Completed
-
Xeris PharmaceuticalsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...CompletedHypoglycemiaUnited States
-
Xeris PharmaceuticalsCompleted
-
University Hospital, Gentofte, CopenhagenCompletedObesity | Incretin ActionDenmark
-
Far Eastern Memorial HospitalRecruitingHysteroscopic MyomectomyTaiwan
-
Jaeb Center for Health ResearchXeris PharmaceuticalsCompletedDiabetes Mellitus, Type 1United States
-
Jaeb Center for Health ResearchXeris PharmaceuticalsCompleted
-
Far Eastern Memorial HospitalCompletedComplication of Surgical ProcedureTaiwan
-
Xeris PharmaceuticalsCompletedHypoglycemia | Diabetes Mellitus, Type 1United States, Canada
-
Massachusetts General HospitalBoston UniversityTerminatedDiabetes Mellitus Type 1United States